Martin Akerman
Principal investigator, leads ENVISAGENICS INC.
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$9.3MFederal grants as PI13 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
13 awards · $9.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 21, 2026 | NIH | SBIR Phase II SpliceDisco: A Machine Learning Tool for the Identification of Alternative Splicing Events Directly Regulated by Pathological Splicing Factors in Cancer | $890K | ENVISAGENICS INC |
| Jul 12, 2023 | NIH | SBIR Phase II Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data | $77K | ENVISAGENICS INC |
| May 18, 2023 | NIH | SBIR Phase II Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data | $980K | ENVISAGENICS INC |
| Jul 1, 2022 | NIH | SBIR Phase II Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data | $2.1M | ENVISAGENICS INC |
| Jun 16, 2022 | NIH | SBIR Phase II Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data | $1.0M | ENVISAGENICS INC |
| Sep 12, 2019 | NIH | SBIR Phase I A Software Platform for the Identification of Cell Surface Antigens Using RNA-seq Data | $302K | ENVISAGENICS INC |
| Sep 12, 2019 | NIH | SBIR Phase I A Software Platform for the Identification of Cell Surface Antigens Using RNA-seq Data | $302K | ENVISAGENICS INC |
| Mar 22, 2019 | NIH | SBIR Phase II SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data | $517K | ENVISAGENICS INC |
| Aug 31, 2018 | NIH | SBIR Phase II SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data | $125K | ENVISAGENICS INC |
| Apr 5, 2018 | NIH | SBIR Phase II SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data | $1.6M | ENVISAGENICS INC |
| Apr 2, 2018 | NIH | SBIR Phase II SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data | $983K | ENVISAGENICS INC |
| Aug 6, 2015 | NIH | SBIR Phase I SpliceCore: A cloud-based platform to detect, quantify and interpret alternative splicing variation from next-generation sequencing data. | $225K | ENVISAGENICS INC |
| Aug 6, 2015 | NIH | SBIR Phase I SpliceCore: A cloud-based platform to detect, quantify and interpret alternative splicing variation from next-generation sequencing data. | $225K | ENVISAGENICS INC |
1 patents as inventor
- US ENVISAGENICS INC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#76
Awards as PI#72
Patents#273
Companies
- ENVISAGENICS INCLeads (SEC Form D) · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.